Arch Biopartners arranges $500,000 private placement with company officer

Arch Biopartners Inc. (TSX Venture: ARCH, OTCQB: ACHFF) announced it has arranged a non-brokered private placement of 480,769 common shares at $1.04 per share for gross proceeds of $500,000 CAD.

The offering involves the issuance of all shares to a company officer, constituting a related party transaction under Multilateral Instrument 61-101. The transaction is exempt from formal valuation and minority shareholder approval requirements as the fair market value does not exceed 25% of the company's market capitalization.

The offering is scheduled to close on November 12, 2025, subject to regulatory approvals including TSX Venture Exchange approval and customary closing conditions. All shares will be subject to a hold period of four months and one day from the closing date, with no finders' fees payable.

Arch stated the proceeds will fund general working capital and operating expenses not covered by the company's human trial funding grants.

The Toronto-based biotech company develops treatments for acute kidney injury and chronic kidney diseases. Its development pipeline includes LSALT peptide in Phase II trials for cardiac surgery-associated acute kidney injury, cilastatin in Phase II trials for toxin-induced acute kidney injury, and a pre-clinical program targeting chronic kidney disease.

The company has 66,356,366 common shares outstanding, according to the press release statement.

You May Also Be Interested In

• Brixton Metals closes second tranche, raising $8.96M total
• American Critical Minerals reprices private placement at $0.20 per unit
• Sun Summit closes $4M private placement for BC exploration